Physician profile
Melvin E Wagner
NPI 1013943950
$5,074.15
in general payments reported to CMS, 2019-2025
28 companies · $933 in 2025
The $933 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $170 · 2021: $440 · 2022: $662 · 2023: $556 · 2024: $1,993 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237 · Travel and Lodging: $1,187 · Education: $58.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.55 |
| Travel and Lodging | $1,187.16 |
| Education | $58.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,175.96 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Regeneron Healthcare Solutions, INC. | $453.93 | 2020-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $425.36 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Abbvie INC. | $323.61 | 2022-2025 | Ozurdex, Lumigan, Alphagan P |
| Sun Pharmaceutical Industries INC. | $281.52 | 2019-2025 | Cequa, Xelpros |
| Novartis Pharmaceuticals Corporation | $256.67 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $231.20 | 2021-2022 | |
| Genentech USA, INC. | $122.51 | 2022-2025 | Vabysmo |
| Allergan, INC. | $98.44 | 2020-2022 | |
| Rxsight INC | $74.93 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $67.42 | 2020-2025 | Sion Surgical Instrument, Omni Surgical System |
| Astellas Pharma US INC | $60.58 | 2024-2025 | Izervay |
| Carl Zeiss Meditec, INC. | $58.44 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $53.52 | 2019-2021 | |
| Shire North American Group INC | $52.89 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $48.53 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $41.31 | 2022-2023 | Syfovre |
| Oyster Point Pharma, INC. | $40.13 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $36.59 | 2024 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $31.34 | 2022 | |
| Harrow Eye, LLC | $22.14 | 2025 | |
| Thea Pharma INC. | $21.54 | 2023 | |
| Ocular Therapeutix, INC. | $20.65 | 2024 | Dextenza |
| Sandoz INC. | $18.14 | 2024 | Cimerli |
| Kala Pharmaceuticals, INC. | $15.35 | 2020 | |
| Omeros Corporation | $15.11 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $13.67 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.